Overview: Rett Syndrome Mutation TestIntroduction: The Rett Syndrome Mutation Test detects MECP2 mutations to diagnose Rett syndrome, causing developmental delays. Aligned with 2023 ACMG guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Rett syndrome.
Other Names: MECP2 Mutation Assay, Rett Syndrome Genetic Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Rett syndrome testing began in the 1990s with MECP2 gene discovery. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects MECP2 mutations to diagnose Rett syndrome, guides treatment, and evaluates patients with developmental delays.
Test Parameters: 1. MECP2 Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of developmental delays or neurological symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document developmental delays, seizures, or family history of Rett syndrome. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, Rett syndrome implications, and risks of sample collection.
Procedural Considerations: Uses PCR or next-generation sequencing to detect MECP2 mutations. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for Rett syndrome diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive MECP2 mutation confirms Rett syndrome, guiding supportive therapies. Negative results may require additional genetic testing.
Specialist Consultation: Consult a geneticist or neurologist for result interpretation and treatment planning.
Additional Supporting Tests: EEG, brain MRI, or clinical evaluation to confirm Rett syndrome diagnosis.
Test Limitations: Not all Rett syndrome cases have MECP2 mutations; clinical correlation is needed. Sample quality affects sensitivity.
References: ACMG Rett Syndrome Guidelines, 2023; American Journal of Medical Genetics, Amir RE, 2022.
